Generic placeholder image

Current Pediatric Reviews

Editor-in-Chief

ISSN (Print): 1573-3963
ISSN (Online): 1875-6336

Clinical Trial

Comparison of the Effectiveness of Beraksurf and Curosurf Exogenous Surfactants in the Treatment of Respiratory Distress Syndrome in Preterm Neonates: A Double-blind Randomized Study in the West of Iran

Author(s): Fatemeh Eghbalian, Behnaz Basiri, Behnaz Hatami, Narges Mohammadi Parsa and Ensiyeh Jenabi*

Volume 21, Issue 2, 2025

Published on: 15 April, 2024

Page: [200 - 206] Pages: 7

DOI: 10.2174/0115733963271143240403070529

Price: $65

Open Access Journals Promotions 2
Abstract

Background: To date, few studies have compared the effectiveness of exogenous surfactant therapy with Curosurf and Beraksurf in the treatment of respiratory distress syndrome (RDS) in preterm neonates.

Objective: Since surfactant has a significant impact on the treatment of neonates with RDS, this study was conducted to introduce a more effective method for treating preterm neonates with RDS.

Methods: The present clinical trial was conducted on 140 preterm neonates with RDS in the NICU department of two specialized university hospitals in Hamadan, western Iran. In one group, we used the Iranian-made surfactant Beraksurf, and in another group, we used the Italian-made surfactant Curosurf. In the end, the checklist for the two groups was completed. Data analysis was performed using SPSS version 22, and a significance level of 5% was considered for all tests.

Results: The comparison of the frequency distribution of maternal corticosteroid administration, response to treatment and need for re-intubation, associated disorders, and mortality among neonates of the two groups of Beracsurf and Curosurf surfactant did not show a significant difference (p=0.962, 0.763, 0.725 and 0.149, respectively). Further, the comparison of the mean number of days requiring respiratory support, days free from respiratory support, and hospitalization days among neonates of the two groups of Beracsurf and Curosurf surfactant injection did not show a significant difference (p=0.910, 0.725, and 0.898, respectively). Additionally, the comparison of the time of initiation of feeding and the time of reaching maximum feeding among neonates of the two groups of Beracsurf and Curosurf surfactant injection also did not show significant differences (p=0.881 and 0.903, respectively).

Conclusion: Based on the fact that Beracsurf and Curosurf surfactants did not show significant differences in the treatment outcomes of RDS in preterm neonates, it is suggested that the Iranianmade surfactant, Beracsurf, should be used for the treatment of these neonates due to its cost-effectiveness and availability compared to Curosurf.

Keywords: Surfactant, respiratory distress syndrome, preterm, Iran, double-blind randomized study, neonate.

« Previous
Graphical Abstract
[1]
Beck S, Wojdyla D, Say L, et al. The worldwide incidence of preterm birth: A systematic review of maternal mortality and morbidity. Bull World Health Organ 2010; 88(1): 31-8.
[http://dx.doi.org/10.2471/BLT.08.062554] [PMID: 20428351]
[2]
Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008; 371(9606): 75-84.
[http://dx.doi.org/10.1016/S0140-6736(08)60074-4] [PMID: 18177778]
[3]
Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature 2005; 438(7070): 960-6.
[http://dx.doi.org/10.1038/nature04482] [PMID: 16355161]
[4]
Stitt AW, Lois N, Medina RJ, Adamson P, Curtis TM. Advances in our understanding of diabetic retinopathy. Clin Sci 2013; 125(1): 1-17.
[http://dx.doi.org/10.1042/CS20120588] [PMID: 23485060]
[5]
Roberts GE, Lacatusu DA, Kester J, Moumoutjis FG, Sidiqi M. Preventative management of sepsis-induced acute respiratory distress syndrome in the geriatric population. Cureus 2023; 15(2): e34680.
[http://dx.doi.org/10.7759/cureus.34680] [PMID: 36909040]
[6]
Miall L. Fanaroff and martin's neonatal-perinatal medicine – diseases of the fetus and infant. Seminars Fetal Neonat Med 2015; 20(4): P281.
[7]
Althouse LA, Stockman JA. Pediatric workforce: A look at neonatal-perinatal medicine data from the american board of pediatrics. J Pediatr 2006; 148(6): 727-9.
[http://dx.doi.org/10.1016/j.jpeds.2006.03.046]
[8]
Seger N, Soll R, Group CN. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Libr 2009; 2010(2): CD007836.
[http://dx.doi.org/10.1002/14651858.CD007836] [PMID: 19370695]
[9]
Victorin LH, Deverajan LV, Curstedt T, Robertson B. Surfactant replacement in spontaneously breathing babies with hyaline membrane disease-A pilot study. Neonatology 1990; 58(3): 121-6.
[http://dx.doi.org/10.1159/000243250] [PMID: 2279046]
[10]
Björklund LJ, Ingimarsson J, Curstedt T, et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr Res 1997; 42(3): 348-55.
[http://dx.doi.org/10.1203/00006450-199709000-00016] [PMID: 9284276]
[11]
Stoll BJ, Hansen NI, Bell EF, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015; 314(10): 1039-51.
[http://dx.doi.org/10.1001/jama.2015.10244] [PMID: 26348753]
[12]
Soll R, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2015; 2001(2): CD000144.
[13]
Singh N, Halliday HL, Stevens TP, Suresh G, Soll R, Reyes RMX. Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2015; 2015(12): CD010249.
[http://dx.doi.org/10.1002/14651858.CD010249.pub2]
[14]
Gharehbaghi MM, Sarbakhsh P, Mohammadbager H, Gharibzadeh S, Shaseb EA. Randomized, single-blind, comparison trial of beractant (beraksurftm) versus poractant alfa (curosurf®) in the treatment of respiratory distress syndrome in preterm infants. Pharm Sci 2022; 29(1): 52-8.
[15]
Mohammadi DP. Comparing the effectiveness of curosurf and beraksurf in the treatment of respiratory distress in premature infants. Int J Pediatr 2020; 10(5): 15992-7.
[16]
Gharehbaghi MM, Sakha SHP, Ghojazadeh M, Firoozi F. Complications among premature neonates treated with beractant and poractant alfa. Indian J Pediatr 2010; 77(7): 751-4.
[http://dx.doi.org/10.1007/s12098-010-0097-y] [PMID: 20589459]
[17]
Akar S, Topcuoglu S, Dincer E, Ozalkaya E, Karatekin G, Yildirim TG. Comparison of efficacy of beractant and poractant treatment performed with minimal invasive technique. Iranian J Nematol 2021; 12(1): 1-6.
[18]
Saeidi R, Hamedi A, Javadi A, Robatsangi GM, Dinparvar SK. Comparison of side effect of survanta and curosurf in decreasing mortality due to respiratory distress syndrome (RDS) in premature infants admitted in NICU of Ghaem Hospital On 2006-2008. Iran J Neonatol 2013; 4(3): 7-12.
[19]
Mussavi M, Mirnia K, Asadollahi K. Comparison of the efficacy of three natural surfactants (Curosurf, Survanta, and Alveofact) in the treatment of respiratory distress syndrome among neonates: A randomized controlled trial. Iran J Pediatr 2016; In Press(In Press): e5743.
[http://dx.doi.org/10.5812/ijp.5743] [PMID: 28203337]
[20]
Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004; 21(3): 109-19.
[http://dx.doi.org/10.1055/s-2004-823779] [PMID: 15085492]
[21]
Dilli D, Çakmakçı E, Akduman H, et al. Comparison of three natural surfactants according to lung ultrasonography scores in newborns with respiratory distress syndrome. J Matern Fetal Neonatal Med 2021; 34(10): 1634-40.
[http://dx.doi.org/10.1080/14767058.2019.1643313] [PMID: 31296073]
[22]
Şimşek KG, Kutman KHG, Canpolat FE, Oğuz ŞS. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome. Clin Respir J 2020; 14(3): 285-90.
[http://dx.doi.org/10.1111/crj.13130] [PMID: 31814293]
[23]
Baske S, Saha S, Pal PP. Comparison between two natural surfactant poractant alfa and bovine lipid extract in respiratory distress syndrome amongst preterm neonates-a quasi-experimental study. Int J Contemp Pediatrics 2021; 9(1): 27.
[http://dx.doi.org/10.18203/2349-3291.ijcp20214848]
[24]
Ramanathan R, Biniwale M, Sekar K, Hanna N, Golombek S, Bhatia J. Synthetic surfactant CHF5633 compared with poractant alfa in the treatment of neonatal respiratory distress syndrome: A multicenter, double-blind, randomized, controlled clinical trial. J Pediatr 2020; 225: 90-96.e1.
[http://dx.doi.org/10.1016/j.jpeds.2020.06.024]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy